NeuroQuest Development Center, Inc., announced they have entered into a service agreement with the University of California, San Diego for collection and processing of blood samples for their U.S. clinical validation trials.
The South Carolina-based biotech company is developing a blood test for early diagnosis of Alzheimer’s disease (AD).
Designed to be an inexpensive, convenient surrogate test for costly positron emission tomography (PET) brain scans, the NeuroQuest blood test can potentially identify a pre-clinical stage of AD in a person years before the onset of noticeable symptoms.
Recent pilot testing of NeuroQuest’s biomarker technology in Australia surpassed current standards of specificity and sensitivity set by the U.S. Alzheimer’s Association.
“Based on our pilot test results, we are cautiously optimistic about our upcoming U.S. clinical trials,” said Dan Touitou, CEO of NeuroQuest. “The larger scope of the Anti-Amyloid in Asymptomatic AD (A4) study will greatly help us determine the validity of our science.”
The A4 study, funded by the National Institute on Aging, Eli Lilly and Company, and several philanthropic organizations, is a national clinical trial for older individuals who may be at risk for AD.
For the full story, please click here.